NEW
YORK, May 10, 2023 /PRNewswire/ -- The Gross Law
Firm issues the following notice to shareholders of Relmada
Therapeutics, Inc.:
Before market opened on October 13,
2022, Relmada announced the results of its RELIANCE III
study (REL-1017-303), evaluating the drug REL-1017 as a monotherapy
for Major Depressive Disorder (MDD). Relmada revealed that the
RELIANCE III trial did not achieve its primary endpoint, which was
a statistically significant improvement in depression symptoms
compared to placebo on Day 28, as measured by the Mongomery-Asberg
Depression Rating Scale (MADRS). Specifically, the REL-1017
treatment showed a MADRS reduction of 14.8 points at Day 28 versus
13.9 points for placebo, a higher-than-expected placebo response.
Relmada described that "[p]aradoxical results were observed in
certain study sites, where placebo dramatically outperformed
REL-1017."
Following this news, Relmada's stock price fell nearly 80% to
close at $6.48 per share on
October 13, 2022. Due to the
forgoing, The Gross Law Firm is investigating potential securities
fraud claims on behalf of certain Relmada investors. If you
incurred a loss on your RLMD investment, please contact us using
the link below to discuss your rights.
https://securitiesclasslaw.com/securities/relmada-loss-submission-form/?from=4
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law Firm is
committed to ensuring that companies adhere to responsible business
practices and engage in good corporate citizenship. The firm seeks
recovery on behalf of investors who incurred losses when false
and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/investigation-alert-the-gross-law-firm-notifies-shareholders-of-relmada-therapeutics-inc-of-an-investigation-and-potential-class-action-lawsuit--nyse-rlmd-301815617.html
SOURCE The Gross Law Firm